



Chemed Corporation (CHE)

Updated July 3rd, 2024, by Yiannis Zourmpanos

Key Metrics

Current Price:	\$540	5 Year CAGR Estimate:	9.1%	Market Cap:	\$8.01 B
Fair Value Price:	\$588	5 Year Growth Estimate:	7.0%	Ex-Dividend Date:	08/12/2024 ¹
% Fair Value:	92%	5 Year Valuation Multiple Estimate:	1.7%	Dividend Payment Date:	09/05/2024 ²
Dividend Yield:	0.3%	5 Year Price Target	\$824	Years Of Dividend Growth:	16
Dividend Risk Score:	A	Retirement Suitability Score:	C	Rating:	Hold

Overview & Current Events

Chemed Corporation (CHE) is a publicly traded company based in Cincinnati, Ohio, that operates two wholly owned subsidiaries: VITAS Healthcare Corporation and Roto-Rooter. The company was founded in 1970 and has established itself as a leading provider of healthcare equipment and services, primarily in end-of-life hospice care through VITAS and plumbing and drain services through Roto-Rooter. Chemed Corporation maintains a strong competitive position in the healthcare and plumbing markets, with revenues of \$2.1 billion in 2022. The company's market share is substantial, with VITAS generating roughly 75% of Chemed Corporation's total revenue and Roto-Rooter accounting for the remaining 25%. The company has a strong management team. Its mission is to provide its customers with high-quality healthcare and plumbing services, making it a trusted and reliable partner in these industries.

On April 24th, 2024, the company announced results for the first quarter of 2024. CHE reported non-GAAP EPS of \$5.20, missing market estimates by \$0.28. In addition, the company reported revenues of \$589.2 million for the quarter, up 5.2% year-over-year.

VITAS Healthcare saw substantial growth, where Net Patient Revenue increased by 14.0% to \$354 million; Average Daily Census (ADC) was up 10.3% to 19,665; and Admissions rose by 4.5% to 16,911. Excluding certain discrete items, VITAS' Net Income surged by 77.6% to \$44.0 million. At the same time, Adjusted EBITDA, excluding Medicare Cap, went up by 67.2% to \$60.7 million and equated to a 544 basis point improvement in the Adjusted EBITDA margin to 17.0%.

In contrast, the Roto-Rooter segment remained under pressure, with revenue down 5.8% at \$235.2 million. Net income, excluding certain discrete items, dropped 15.8% to \$42.7 million, while adjusted EBITDA slid 15.6% to \$60.7 million, and adjusted EBITDA margin lowered by 299 basis points to 25.8%. Chemed revised its non-GAAP measures to include the Retention Program costs for current and prior periods beginning with the September 30, 2023 quarter.

Management reaffirms its full-year 2024 earnings per diluted share guidance range of \$23.30 to \$23.70, excluding non-cash stock option expenses, tax benefits from stock option exercises, litigation costs, and other discrete items, with updated guidance and subsidiary metrics to be provided in the June 30, 2024 earnings release.

Growth on a Per-Share Basis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
EPS	\$5.57	\$6.33	\$6.48	\$8.43	\$11.93	\$13.95	\$18.08	\$19.35	\$19.70	\$17.93	\$23.50	\$32.96
DPS	\$0.84	\$0.92	\$1.00	\$1.08	\$1.16	\$1.24	\$1.32	\$1.40	\$1.48	\$1.56	\$1.60	\$2.04
Shares³	16.9	16.8	16.2	16.0	15.9	15.9	15.9	14.9	15.0	15.1	14.9	14.0

By 2030, 21% of the population is anticipated to be over 65. This suggests that many more Americans than today will require the healthcare services offered by VITAS. Therefore, the management has guided towards revenue growth between 6.0% and 7.0% for 2024.

¹ The ex-dividend date is estimated based on historical data.

² The dividend payment date is estimated based on historical data.

³ In millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Chemed Corporation (CHE)

Updated July 3rd, 2024, by Yiannis Zourmpanos

Chemed Corporation has effectively utilized the CARES Act during the pandemic and boosted its operating profits. However, these non-recurring benefits are gone, and we consider a growth rate in the high single digits to be more representative of its prospects. We matched the midpoint of management’s guidance for 2024, forecasting an EPS of \$23.50, and using a projected annual growth of 7.0% for the next five years, which is lower than its 10-year CAGR of 13.9%, to get an EPS estimate of \$32.96 by 2029. Moreover, Chemed Corporation's DPS had a 10-year and five-year CAGR of 7.1% and 16.0%, respectively. CHE has consistently increased its dividend distribution in the past 16 years, and we believe that DPS will grow slightly slower than EPS growth at an annual rate of 5.0%.

Valuation Analysis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Now	2029
Avg. P/E	17.2	20.9	21.5	24.2	25.2	26.8	26.0	24.8	24.5	29.7	23.0	25.0
Avg. Yld.	0.9%	0.7%	0.7%	0.5%	0.4%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.2%

The company’s largest revenue contributor, VITAS, has significant tailwinds, such as the aging US population, that will support its growth for the foreseeable future. Chemed Corporation is trading at a forward P/E of 23.0, lower than its five-year average of 26.4 and 10-year average of 24.1. However, considering the growth prospects, we have assumed a target P/E of 25.0 by 2029, close to its historical averages, and suggests a target price of \$824.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Payout	15%	15%	15%	13%	10%	9%	7%	7%	8%	9%	7%	6%

The company's competitive advantage lies in its ability to provide high-quality hospice care to terminally ill patients through VITAS, one of the largest hospice care providers in the US. The company's recession performance has been relatively stable due to the essential nature of its healthcare services, and it has demonstrated consistent revenue growth and profitability over the years. Chemed Corporation has a moderate level of debt, with a debt-to-equity ratio of around 13%, indicating that it has utilized debt financing to some extent but has yet to over-leverage its balance sheet. During Q1 2024, Chemed repurchased 50,000 shares for \$32.3 million at an average cost of \$646.87 per share, with approximately \$281.7 million remaining under its share repurchase authorization as of March 31, 2024.

Final Thoughts & Recommendation

We remain confident in Chemed Corporation’s prospects, as its outlook is still favorable, and there are some strong tailwinds. However, we believe that investors should wait for a better entry point. Thus, the hold rating is premised upon the 9.1% annualized total returns for the medium-term, derived from the forecasted earnings-per-share growth of 7.0%, the 0.3% dividend yield, and a small valuation tailwind.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Chemed Corporation (CHE)

Updated July 3rd, 2024, by Yiannis Zourmpanos

Income Statement Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Revenue	1,456	1,543	1,577	1,667	1,783	1,939	2,080	2,139	2,135	2,264
Gross Profit	422	456	461	516	555	617	701	770	765	799
Gross Margin	29.0%	29.5%	29.3%	31.0%	31.1%	31.8%	33.7%	36.0%	35.8%	35.3%
SG&A Exp.	223	238	248	277	271	306	330	367	359	395
D&A Exp.	31	33	35	36	39	45	57	59	59	61
Operating Profit	168	184	179	204	245	267	390	344	347	343
Op. Margin	11.6%	12.0%	11.3%	12.2%	13.7%	13.7%	18.7%	16.1%	16.3%	15.2%
Net Profit	99	110	109	98	206	220	319	269	250	273
Net Margin	6.8%	7.1%	6.9%	5.9%	11.5%	11.3%	15.4%	12.6%	11.7%	12.1%
Free Cash Flow	67	127	96	98	234	248	430	250	253	273
Income Tax	63	70	68	19	34	42	77	82	80	78

Balance Sheet Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total Assets	860	852	880	920	976	1,268	1,435	1,343	1,442	1,668
Cash & Equivalents	14	15	15	11	5	6	163	33	74	264
Acc. Receivable	125	106	132	114	120	144	127	137	139	182
Inventories	6	6	6	5	6	7	7	10	10	12
Goodwill & Int.	523	527	527	532	579	704	697	687	681	675
Total Liabilities	409	339	356	380	384	542	534	719	643	560
Accounts Payable	47	44	40	48	50	51	54	73	42	48
Long-Term Debt	148	91	109	101	89	90	-	185	98	16
Total Equity	451	513	524	540	591	727	901	623	799	1,108
LTD/E Ratio	0.33	0.18	0.21	0.19	0.15	0.12	-	0.30	0.12	0.01

Profitability & Per Share Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Assets	11.3%	12.9%	12.6%	10.9%	21.7%	19.6%	23.6%	19.3%	17.9%	17.5%
Return on Equity	22.1%	22.9%	21.0%	18.4%	36.3%	33.4%	39.3%	35.2%	35.1%	28.6%
ROIC	16.1%	18.3%	17.6%	15.4%	31.1%	29.4%	37.2%	31.4%	29.3%	27.0%
Shares Out.	16.9	16.8	16.2	16.0	15.9	15.9	15.9	14.9	15.0	15.2
Revenue/Share	81.63	88.59	93.92	99.55	106.09	117.30	126.82	134.22	141.40	148.97
FCF/Share	3.74	7.31	5.70	5.87	13.94	15.02	26.25	15.68	16.73	17.99

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.